De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TheraVet Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Enrico Bastianelli

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

CEO

Enrico Bastianelli (55 yo)

6.9yrs

Tenure

Mr. Enrico Bastianelli, MD, MBA, serves as Chief Executive Officer of TheraVet SA and also serves as its Director since November 22, 2017. He is Founder of TheraVet SA. He is the Founder and Strategic Advi...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Enrico Bastianelli	Founder	6.9yrs	geen gegevens	geen gegevens
Simon Wheeler	Independent Chairman	2.8yrs	geen gegevens	geen gegevens
Nesya Goris	Independent Director	2.8yrs	geen gegevens	geen gegevens
Olivier Gauthier	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marc Balligand	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Guillaume Ragetly	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ulrich Rytz	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van ALVET wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

TheraVet Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

TheraVet SA, Annual General Meeting, Jun 05, 2025

TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First half 2024 earnings released: €0.26 loss per share (vs €0.28 loss in 1H 2023)

New major risk - Revenue size

TheraVet SA, Annual General Meeting, Jun 05, 2025

TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study

New major risk - Financial position

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

TheraVet SA Announces the Launch of BIOCERA-VET Equine

TheraVet SA Announces Commercial Launch of Biocera-VET in Germany

TheraVet Announces Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy

TheraVet SA Announces Launch of Biocera-Vet Canine Osteosarcoma Study Conducted by the University of Florida

TheraVet SA announced that it expects to receive €1 million in funding

TheraVet SA announced that it expects to receive €1 million in funding

TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer

New major risk - Share price stability

TheraVet SA Announces Patient Recruitment Phase Successfully Completed in Biocera-Vet Fracture Revision Surgery Study in Toy Dogs

First half 2023 earnings released

TheraVet SA to Report First Half, 2024 Results on Sep 12, 2024

TheraVet SA Announces the Commercial Launch of A Local and Sustained Antibiotic Releasing Bone Substitute

Full year 2022 earnings released

Less than half of directors are independent

TheraVet SA to Report First Half, 2023 Results on Sep 06, 2023

First half 2022 earnings released: EPS: €0 (vs €0.24 loss in 1H 2021)

TheraVet SA to Report First Half, 2022 Results on Sep 09, 2022

TheraVet Announces the Commercial Launch of its BIOCERA-VET Product Line in the United States of America

TheraVet SA Announces the Commercial Launch of the Bone Substitutes in the Veterinary Market

Less than half of directors are independent

TheraVet SA to Report Fiscal Year 2021 Results on Apr 06, 2022

TheraVet SA Broadens Bone Substitutes Portfolio with an Innovative Line of Biological Bone Grafts

TheraVet SA presents Positive Results of Biocera-Vet-Bone Surgery Presented at the Annual Conference of the US Veterinary Orthopedic Society and Confirmed on a Larger Patients Cohort

Theravet Announces Commercial Launch of Biocera-Vet® for Canine Osteosarcoma in Belgium, France and the Netherlands

TheraVet Announces the Launch of the Pivotal European Multicentric Clinical Study of VISCO-VET in Canine Osteoarthritis

TheraVet Announces Positive Safety and Efficacy Results for VISCO-VET in Canine Osteoarthritis

TheraVet Extends the Use of BIOCERA-VET to a New Curative Approach of Osteosarcoma in Dogs Through an Innovative and Multidisciplinary Management

CEO

Tenure

Bestuursleden

Gemiddelde duur